The safety and pharmacokinetics of ABI-5366, a novel, oral, long-acting HSV helicase-primase inhibitor: Interim results from a Phase 1a/1b study in healthy participants

ABI-5366 - Assembly Biosci

A. Gaggar; E. Gane; C. Schwabe; G. Wang; J. Liu; S. Knox; K. Kitrinos; K. Zomorodi

Feb 4, 2025